Page 2 - Daniel Spratt News Today

Daniel Spratt, MD, discusses the expanded role of radiation therapy for the treatment of patients with prostate cancer, delves into the optimal approach for using radiation in tandem with hormonal therapy for these patients, and highlights ongoing research focused on minimizing adverse effects associated with radiotherapy.

But agency doesn't plan to immediately push for KRAS inhibitor's withdrawal

Findings presented at the 2023 ASTRO Annual Meeting expand substantial body of evidence demonstrating Decipher Prostate test’s ability to help inform prostate cancer treatment...

A predictive model based on artificial intelligence may guide the use of androgen deprivation therapy for men with intermediate-risk prostate cancer.

A predictive model based on artificial intelligence may guide the use of androgen deprivation therapy for men with intermediate-risk prostate cancer.

Artificial intelligence was used to develop a predictive biomarker to identify patients with intermediate-risk prostate cancer who would benefit from adding androgen deprivation therapy to radiotherapy.

A predictive artificial intelligence (AI) biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer was validated in a recent study published in NEJM Evidence.

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

SAN FRANCISCO--(BUSINESS WIRE)--Jun 29, 2023--

Delayed testing and less access to tailored, advanced treatments drive higher mortality rates for Black men with prostate cancer compared to other men.